GSE185872 methotrexate macrophage 0 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE185872_methotrexate_macrophage_0_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE185872_methotrexate_macrophage_0_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE185872_methotrexate_macrophage_0_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE185872_methotrexate_macrophage_0_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

small nucleolar RNA host gene 7

Gene

C10orf95 antisense RNA 1

Gene

ITFG2 antisense RNA 1

Gene

interferon stimulated noncoding RNA 1

Gene

BARX1 divergent transcript

Gene

pyrin domain containing 5

Gene

uncharacterized LOC101927040

Gene

long intergenic non-protein coding RNA 1585

Gene

CRADD antisense RNA 1

Gene

long intergenic non-protein coding RNA 1267

  • Gene

    small nucleolar RNA host gene 7


  • Gene

    C10orf95 antisense RNA 1


  • Gene

    ITFG2 antisense RNA 1


  • Gene

    interferon stimulated noncoding RNA 1


  • Gene

    BARX1 divergent transcript


  • Gene

    pyrin domain containing 5


  • Gene

    uncharacterized LOC101927040


  • Gene

    long intergenic non-protein coding RNA 1585


  • Gene

    CRADD antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 1267

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.